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Abstract
Background: The peritoneal carcinomatosis index (PCI) can be used to quantify the tumor burden in patients
with advanced ovarian cancer. The aim of the present study was to establish a predictive model for suboptimal
cytoreductive surgery (SCS) (residual tumor of > 1 cm) using preoperative and intraoperative determination of the PCI.
Methods: In total, 110 consecutive patients treated for advanced ovarian cancer during a 4-year period in our institution
were assessed. Eighty of these patients were eligible for primary debulking surgery and thus included in the present
study. All data were prospectively collected and retrospectively evaluated. We determined the PCI both preoperatively
and intraoperatively and assessed postoperative complications.
Results: A PCI of > 20 was the best cut-off with which to predict a risk of SCS among all three diagnostic techniques
assessed in this study (computed tomography, laparoscopy, and laparotomy). Intraoperative PCI determination was
associated with the lowest risk of false negatives for SCS when detecting a PCI of < 20. The combination of preoperative
computed tomography and laparoscopy, when both techniques predicted SCS, was associated with the lowest risk of
false positives for SCS when detecting a PCI of > 20.
Conclusion: The combination of computed tomography and laparoscopy to obtain the PCI can help to determine
which patients with advanced ovarian cancer are suitable for primary debulking surgery and which should undergo
neoadjuvant chemotherapy.
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Background
Ovarian cancer is a major cause of gynecologic cancer-
related death in women despite treatment advances during
the past few decades. Ovarian cancer accounts for 5% of
all cancers among women and causes more deaths than
any other female genital tract cancer. Approximately 8 in
100,000 women per year in Spain will develop ovarian
cancer [1].
Approximately 70 to 80% of ovarian cancers are diag-
nosed at an advanced stage (stage III and IV). For this
group of patients, the 5-year survival rate is lower than
20 to 30% [1]. The gold standard treatment of ovarian
cancer has remained the same over the last few decades,
consisting of primary cytoreductive surgery to resect as
much diseased tissue as possible followed by platinum-
based chemotherapy [2].
Surgery is considered essential for treatment of advanced
epithelial ovarian cancer (AOC). In general, cytoreductive
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surgery is initially performed for AOC, including stage IV,
when distant metastatic lesions develop and do not influ-
ence survival in the short term. The ultimate goal of cytor-
eductive surgery is removal of the entire tumor burden to
achieve either complete removal of the tumor upon visual
inspection (complete cytoreductive surgery, CCS) or a re-
sidual tumor of < 1 cm (optimal cytoreductive surgery,
OCS). Only these two surgical outcomes will improve sur-
vival [3].
Intraperitoneal spread of ovarian cancer is the most typ-
ical presentation of stage III and IV ovarian cancer. Vari-
ous assessment tools in the field of surgical oncology have
been described to objectively evaluate and quantify the
tumor burden in patients with these AOC stages. One of
the most frequently used tools is the peritoneal carcin-
omatosis index (PCI) for peritoneal carcinomatosis of all
types, first described by Sugarbaker and Jablonski [4].
Fagotti et al. [5], Aletti et al. [6], and Zivanovic et al. [7]
have also described other assessment tools specifically for
ovarian cancer. These assessment tools are based on
tumor size and/or location within the peritoneal cavity.
One series regarding debulking or cytoreductive sur-
gery for treatment of AOC demonstrated cytoreduction
rates of 15 to 85%. In most such reports, when the OCS
is > 50%, upper abdominal surgery (UAS) is employed
[8]. However, these extensive surgical procedures to
achieve complete cytoreduction are associated with post-
operative morbidity rates ranging from 11.0 to 67.0%
and postoperative mortality rates ranging from 0.0 to
6.7% [9].
Based on these data, the gynecologic oncologist must
decide between efficacy and safety when performing
these procedures. Neoadjuvant chemotherapy (NACT)
and interval debulking surgery are valid alternatives in
patients for whom high complication rates are expected
(e.g., severe comorbidities, poor performance status) or
when unresectable disease is identified prior to surgery.
Therefore, one of the key points of surgical treatment is
to predict whether the surgical team will be capable of
performing OCS. In this context, some predictive cytore-
duction models have been described during the last few
years [5].
The aim of this study was to establish a predictive
model for suboptimal cytoreductive surgery (SCS) based
on our experience with preoperative and intraoperative
determination of the PCI by computed tomography
(CT) and laparoscopy at the Multidisciplinary Unit for
Abdominal Pelvic Oncology Surgery (MUAPOS).
Methods
In total, 110 consecutive patients with AOC were treated
at the MUAPOS of the University General Hospital of
Castellon (Spain) from January 2013 to December 2016.
The risk of suboptimal cytoreductive surgery was
evaluated with the radiologic-laparoscopic criteria for
unresectability (RLCU) (Table 1) in the preoperative
studies. Age and health status were also taken into ac-
count. All procedures were carried out by the same sur-
gical team.
The PCI was determined in all patients by preoperative
laparoscopy (49 patients) and/or thoracoabdominal CT
(80 patients). To quantify the radiological PCI, the largest
tumor implant was chosen in the assessed region, and a
score was assigned from 0 to 3 points. The sum of the
score assigned to each region results in the radiological
PCI which varies between 1 and 39 points as the operative
index. The PCI was calculated before and during surgery
and was categorized into three ordinal levels: 1–10, 11–
20, and > 20. The best PCI cut off for SCS was calculated
with a ROC curve [10]. All patients’ clinical and patho-
logical characteristics, surgical procedures, and residual
disease at surgery were prospectively collected and retro-
spectively analyzed for the purpose of this study.
With respect to the presence of a residual tumor at
the end of surgery, CCS was defined as no residual
macroscopic tumor, OCS was defined as a residual
tumor of < 1 cm, and SCS was defined as a residual
tumor of > 1 cm. Postoperative complications were de-
scribed according to the Clavien–Dindo classification
[11]. Grade ≥ II complications were considered major
complications. The relationship between major compli-
cations and visceral resections was analyzed with a cu-
mulative sum (CUSUM) graph of cumulative risk
proposed by Royston [12]. All specimens were collected
and labeled relating the PCI areas. The study was ap-
proved by the ethics committee of our institution.
The sensitivity (SEN), specificity (SPC), positive pre-
dictive value (PPV), and negative predictive value (NPV)
were calculated for each investigated parameter. SEN
was defined as the number of patients with a residual
tumor of > 1 cm at surgery (SCS) who were correctly
identified (true positives) divided by the total number of
patients who underwent SCS (true positives + false nega-
tives). SPC was defined as the number of patients with a
residual tumor of < 1 cm at surgery (CCS + OCS) who
were properly identified (true negatives) divided by the
total number of patients who underwent CCS +OCS
(true negatives + false positives). The PPV was calcu-
lated as the number of true positives divided by the
number of total positives (true positives + false
Table 1 Radiologic-laparoscopic criteria for unresectability
CT scan Lung metastasis
Hepatic metastasis in three or
more hepatic segments
Severe hepatic pedicle involvement
Progression after NACT
Diagnostic laparoscopy Diffuse serous small bowel disease
CT computed tomography, NACT neoadjuvant chemotherapy
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positives). The NPV was defined as the number of true
negatives divided by the number of total negatives (false
negatives + true negatives).
Spearman’s rho correlation coefficient was calculated
to analyze the association between quantitative and or-
dinal variables. STATA v12 software was used for statis-
tical analysis. A p value of < 0.05 was considered
statistically significant.
Results
From January 2013 to December 2016, 110 patients sus-
pected to have AOC were treated at the MUAPOS at
the University General Hospital of Castellon (Spain).
Among them, 80 patients where eligible for primary
debulking surgery (PDS) and were included in this study.
None of these patients met our radiologic-laparoscopic
criteria for unresectability (RLCU) (Table 1). Thirty
patients (27.2%) who underwent neoadjuvant chemo-
therapy followed by interval debulking surgery were ex-
cluded from the study.
The clinicopathologic characteristics of all patients are
summarized in Table 2. Most patients presented with
serous (55%), FIGO stage IIIC (69%) epithelial ovarian
cancer. At laparotomy, CCS and OCS were achieved in
64 (80.0%) and 5 (6.2%) patients, respectively, while SCS
was achieved in the remaining 11 (13.8%) patients.
The area under the receiver operating characteristic
curve showed that the best cut-off for predicting a risk
of SCS was a PCI of > 20 for the three diagnostic tech-
niques (CT, laparoscopy, and laparotomy). Preoperative
CT predicted possible SCS (PCI > 20) in nine (11%) pa-
tients. In eight (16%) patients, preoperative laparoscopy
predicted possible SCS (PCI > 20). In 21 (26%) patients,
PCI determination at the start of surgery predicted
possible SCS (PCI > 20). Table 3 shows the diagnostic
parameters of the three techniques in the prediction of
SCS risk.
Thus, the diagnostic technique with the lowest risk of
false negatives for SCS (27%) when detecting a PCI of <
20 was intraoperative PCI determination. The diagnostic
technique with the lowest risk of false positives for SCS
(2%) when detecting a PCI of > 20 was the combination
of preoperative CT and laparoscopy when both tech-
niques predicted SCS.
The surgical procedures performed in all series in-
cluded abdominal and pelvic peritonectomy in 54 (67%)
patients, rectosigmoidectomy in 35 (43%), and large
bowel resection in 40 (50%). Among them, UAS was re-
quired in 57 (71%) patients, including diaphragmatic
peritonectomy in 40 (50%), distal pancreatectomy in 8
(10%), splenectomy in 23 (28.7%), and liver resection in
9 (11%). Major postoperative complications (Clavien–
Dindo grade II–IV) were found in 45 (56%) patients.
Grade III to IV complications were found in 33 (37%)
patients, with a higher incidence at a PCI of > 10 (p <
0.001). The highest rate of postoperative complications
were found when PCI > 20 (p < 0.01). The number of vis-
ceral resections was correlated with the intraoperative
PCI (p < 0.001). The CUSUM graph [11] of the cumula-
tive risk of major postoperative complications by the
number of visceral resections showed that the risk of
postoperative complications progressively increased
from three visceral resections (p < 0.001) until a max-
imum level was maintained from eight visceral resec-
tions (Fig. 1). The 90-day postoperative mortality rate
was 3.7% (3 patients) and was mainly related to the
number of visceral resections (p = 0.009). The number of
visceral resections was correlated with the intraoperative
PCI (p < 0.001).
Discussion
Prediction of surgical outcomes in patients with AOC is
a current surgical dilemma. Surgery remains the corner-
stone of treatment for advanced disease, but it is not ap-
plicable to all patients. NACT remains the best option
for patients who are not surgical candidates [13]. Ver-
gote et al. [14] reported similar survival with PDS and
Table 2 Clinicopathologic characteristics of all patients
Characteristics Nr. (%)
All cases 80
Age, median (range), years 59 (30–84)
FIGO stage
III c 55 69
IV 25 31
Ascites
Yes 22 27.5
No 58 72.5
Histology
Serous 44 55
Endometrioid/clear cells 12 15
Mucinous 8 10
Other adenocarcinoma 16 20
PCI, median (range) 12 (2–35)
PCI 1–10 34 42.5
PCI 11–20 25 31.2
PCI > 20 21 26.2
Duration of surgery,
median (range)
360 (60–638)
Residual tumor
CCS 64 80
OCS 5 6.2
SCS 11 13.8
PCI peritoneal carcinomatosis index, CCS complete cytoreductive surgery, OCS
optimal cytoreductive surgery, SCS suboptimal cytoreductive surgery
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with NACT in stages III and IV ovarian cancer but these
results received multiple criticisms because of the design
of the study with an overall rate of complete cytoreduc-
tion of 19.4% at PDS; actually, these results are not in
the general philosophy of treatment of this disease.
Intraperitoneal spread is the most typical presentation
of stage III and IV ovarian cancer. Unfortunately, the
FIGO system fails in characterization of tumor burden
and in describing anatomical regions affected. The PCI
describes precisely the anatomic regions affected and ob-
jectively quantifies the tumor volume. Tumor load is an
important prognostic factor and should guide the treat-
ment strategy, patients with stage IIIc and less extensive
metastatic tumors had higher survival with PDS while
patients with stage IV disease and large metastatic tu-
mors had higher survival with NACT and IDS [15]. In
our data, 11 patients had SCS, 7 (64%) cases were FIGO
stage IV, and more than 50% of them have a PCI > 20.
With the present model, we should send them to
NACT.
The best method for choosing between PDS and
NACT is still not universally defined. In this paper, we
describe a combination of methods that can be useful to
predict the outcome of AOC or SCS surgery based on
preoperative quantification of the PCI.
The accuracies of CT and diagnostic laparoscopy in
preoperative quantification of the PCI were similar in
the present study. CT might be better able to quantify
the tumor burden affecting strategic anatomic land-
marks, which is a contraindication for initial surgery. At
the same time, laparoscopy allows for visualization of
diffuse serous small bowel disease, which is another
contraindication for PDS (Table 1).
Prediction of OCS or SCS remains a key factor in
AOC treatment. Some authors have described CT as the
best method with which to predict the surgical outcome.
In fact, the accuracy of CT in detecting tumor implants
has ranged from 60 to 90% in some series (Table 4). Car-
cinomatosis affecting the pelvic sidewall and extensive
upper abdominal disease with tumor involvement of the
diaphragm, liver, porta hepatis, and lesser omentum have
traditionally been considered reasons to abandon PDS
and instead perform NACT [16–20].
In the present study, UAS was required in 57 (71%)
patients; this is not currently considered a contraindica-
tion for PDS in centers with an aggressive surgical
protocol and higher rates of OCS [21, 22]. The results
shown in Table 5 reflect the difficulty of reproducing dif-
ferent predictive models in different patient populations
with different surgeons. With our 86% rate of OCS, it is
very difficult to obtain a high PPV for SCS by radiology
or another technique (Table 5). OCS varies among
institutions, and surgeons’ efforts are influenced by their
surgical skills, training, and policy toward this type of
surgery in their institution. This demonstrates the
surgeon-dependent nature of the cytoreductive surgery
outcome. The results of the preoperative CT evaluation
Table 3 Diagnostic parameters for SCS by technique
SEN (95% CI) SPC (95% CI) PPVa (95% CI) NPVa (95% CI)
CT scan 27% (6–61) 91% (82–97) 33% (8–70) 89 (79–95)
Laparoscopy 38% (9–76) 88% (74–96) 33% (6–73) 90 (76–97)
Laparotomy 73% (39–94) 81% (70–90) 38% (18–62) 95% (86–99)
CT plus laparoscopyb 38% (14–69) 98% (87–99) 75% (27–98) 91% (82–96)
SCS suboptimal cytoreductive surgery, 95%CI 95% confidence interval, SEN sensitivity, SPC specificity, PPV positive predictive value, NPV negative predictive value,
CT computed tomography
aFor an SCS prevalence of 13.8%
bCriteria for SCS: CT plus laparoscopy positive for SCS if both show a PCI of > 20
Fig. 1 CUSUM graph relationship between visceral resections and
postoperative complications
Table 4 Studies using CT to predict surgical outcome
Study n OCS (%) SEN (%) SPC (%) PPV (%) NPV (%)
Nelson 42 69 92 71 67 94
Meyer 28 57 58 100 100 55
Bristow 41 49 100 85 87 100
Dowdy 87 71 64 81 57 85
Llueca 80 86 91 27 89 33
CT computed tomography, OCS optimal cytoreductive surgery, SEN sensitivity,
SPC specificity, PPV positive predictive value, NPV negative predictive value
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depend on the results of OCS; higher OCS rates are as-
sociated with lower PPVs on the CT evaluation for SCS.
Because of difficulties in predicting SCS using only im-
aging techniques, some investigators have explored
laparoscopy for the prediction of resectability in patients
with AOC. Fagotti et al. [5] described a laparoscopic
model based on a scoring system from 0 to 12 for pro-
gressive disease. The authors reported an overall OCS
rate of 67%. This model has a good PPV for OCS and an
acceptable NPV for scores of < 2 and > 8. For scores of 2
to 8, however, the surgeon encountered a variable rate of
unnecessary exploration. External validation of this score
was performed by Brun et al., who reported that an OCS
rate of 69% had an SEN, SPC, PPV, and NPV of 46, 89,
89, and 44%, respectively, with a decreased accuracy of
60% [23]. Petrillo et al. [24] recently increased their OCS
rate to 80% by introducing UAS into their procedures.
Once again, the key point is the relationship between
surgeon-related factors and the surgical outcome; a
better-trained surgical team will produce a lower failure
rate in terms of the PPV for OCS, and this may vary
with time. Based on our results, the best individual
method with which to predict the outcome of AOC sur-
gery is the first inspection during the initial laparotomy.
However, we obtained better results when combining
preoperative CT and laparoscopy for OCS when they
both revealed a PCI of < 20 (SEN, 98%; SPC, 38%; PPV,
91%; and NPV, 75%). This means that only 9% (1 − PPV)
of patients are at risk for unnecessary exploration.
Moreover, according to our 13.8% prevalence of SCS
and with a PCI cut-off of 20 (Table 3), the best rate of a
correct diagnosis with SCS (PPV) was obtained by the
combination of preoperative CT and laparoscopy (75%).
However, the PPV and NPV depend on the SCS rate
achievable by the surgical team, assuming the same SEN
and SPC as those obtained in the present study. Table 5
shows the possible variations in PPV and NPV depend-
ing on the SCS rate.
From Table 5, we can deduce that the final reliability
(PPV) in the prediction of SCS according to our criteria
and PCI cut-off may be acceptable for SCS rates of ≥
20%. This is extendable to any predictive diagnostic
model for SCS regardless of the criteria used to predict
SCS because predictive values depend on the prevalence
of SCS for a specific SEN and SPC (those shown in the
present study). Thus, only one model that offers a very
high SEN and SPC will derive acceptable predictive
values even with a low prevalence of SCS.
Visceral resections were performed in 85% of patients.
A CUSUM graph of the cumulative risk of major com-
plications by the number of visceral resections was cre-
ated to evaluate the relationship between visceral
Table 5 Predictive values depending on prevalence of SCS (CT +
laparoscopy)
SCS: prevalence SCS: PPV SCS: NPV
10% 68% (17–98) 93% (85–98)
20% 83% (40–99) 86% (76–93)
30% 89% (55–99) 79% (67–88)
40% 93% (65–99) 70% (58–81)
50% 95% (72–99) 61% (48–73)
For sensitivity of 38% and specificity of 98%
SCS suboptimal cytoreductive surgery, CT computed tomography, PPV positive
predictive value, NPV negative predictive value
Fig. 2 MUAPOS guide to manage AOC. MUAPOS Multidisciplinary Unit for Abdominal Pelvic Oncology Surgery, AOC advanced epithelial ovarian
cancer, PDS primary debulking surgery, IDS interval debulking surgery, CHT chemotherapy, NACT neoadjuvant chemotherapy, RLCU radiologic-
laparoscopic criteria for unresectability
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resections and complications. This graph shows the cu-
mulative sum of observed minus expected postoperative
complications (expected = 56%) by the number of vis-
ceral resections, which proves a clear relationship be-
tween the two factors (Fig. 1). Some authors have
reported that an increased number of visceral resections
increases the morbidity [25]. In the present study, the
highest rate of complications occurred in association
with eight or more visceral resections, and three or more
visceral resections were performed in all patients with a
PCI of > 20. In our results, 21 patients had PCI > 20, 11
with SCS, and 10 with OCS but the last ones suffered a
high rate of complications. Well-trained surgeons can
perform incredible surgeries even in high PCI, but based
on our results, we demonstrate that PCI is correlated
with the number of complications. We believe that
higher PCI (> 20) should go to NACT in order to assure
the security of patients.
It is possible that a multimodal model may overcome
the individual limitations of the herein discussed
methods to predict OCS or SCS. Our management and
treatment protocol for AOC balances both effectiveness
and patient safety (Fig. 2).
This multimodal method of managing the surgical ap-
proach to AOC treatment is based on the results of the
present study, and we combine CT and laparoscopy to
determine which patients are suitable for PDS and which
should undergo NACT with an acceptable OCS rate and
minimal postoperative complications. Other individual
characteristics such as the performance status, age, and
nutritional status are also taken into account before
making the final decision [26].
Conclusion
In conclusion, every individual method employed to pre-
dict the surgical outcome in patients with AOC has its
own limitations; perhaps a multimodal model may over-
come these limitations. Nevertheless, due to the
surgeon-dependent nature of this disease, any model
employed should be individualized for the surgical team
and should be evolutional over time as the surgeons’ ef-
fectiveness improves.
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